中国药科大学学报2017，Vol.48Issue(3)：361-370,10.DOI:10.11665/j.issn.1000-5048.20170318
吲哚胺2,3-双加氧酶1抑制剂的研究进展
Advances in indoleamine 2, 3-dioxygenase 1 inhibitors
程雨兰 1门金霞 1周金培 1张惠斌1
作者信息
- 1. 中国药科大学药物化学教研室,南京210009
- 折叠
摘要
Abstract
Indoleamine 2,3-dioxygenase 1 (IDO1) is the rate-limiting enzyme which catalyses the metabolism of L-tryptophan(L-Trp) in the kynurenine pathway.It is overexpressed in many tumor cells and antigen presenting cells.This enzyme inhibits local immune response and supports tumor cells to evade immune surveillance by depleting L-Trp and producing kynurenine metabolites,thus,it is an important target for cancer immunotherapy.There are several IDO1 inhibitors with different scarfold under investigation,three of which have already entered clinical stage.The role of IDO1 in tumor immune tolerance and the research progress on IDO1 inhibitors in recent years are summarized in this paper.关键词
吲哚胺2,3-双加氧酶1/抑制剂/肿瘤/免疫疗法Key words
indoleamine 2,3-dioxygenase 1/inhibitors/tumor/immunotherapy分类
医药卫生引用本文复制引用
程雨兰,门金霞,周金培,张惠斌..吲哚胺2,3-双加氧酶1抑制剂的研究进展[J].中国药科大学学报,2017,48(3):361-370,10.
